As GLP-1 agonists have garnered attention for management of obesity due to their effect on reducing insulin sensitivity, they are now being considered a therapeutic option for the treatment of PCOS (polycystic ovarian syndrome), one of the most common causes of subfertility, diagnosed via Rotterdam’s criteria: oligomenorrhea, hyperandrogenism and polycystic ovaries (97). Here, GLP1R is linked to obesity due to melanocortin 4 receptor deficiency.